![](images/null.gif) |
![](images/null.gif) |
![](images/null.gif) |
|
Safety of Ledipasvir/Sofosbuvir with and without Ribavirin for the Treatment of Patients with Chronic HCV Genotype 1 Infection: An Analysis of the Phase 3 ION trials
|
|
|
Reported by Jules Levin
IAS 2015
The 8th IAS Conference on HIV Pathogenesis, Treatment and Prevention (IAS 2015), 19-22 July 2015, Vancouver, Canada
N Bräu1, S Alqahtani2, N Afdhal3, S Zeuzem4, S Gordon5, A Mangia6, JC Yang7, J Wolf7, X Ding7, PS Pang7, MS Sulkowski2
1Mount Sinai School of Medicine, Division of Infectious Diseases and Liver Diseases, Astoria, New York, United States; 2Johns Hopkins Medical Center, Baltimore, Maryland, United States;3Beth Israel Deaconess Medical Center, Boston, Massachusetts, United States; 4Johann Wolfgang Goethe University, Frankfurt, Germany; 5Henry Ford Health System, Detroit, Michigan, United States; 6Casa Sollievo della Sofferenza Hospital, San Giovanni Rotondo, Italy; 7Gilead Sciences, Inc., Foster City, California, United States
![ICAAC1.gif](../images/092515/092515-6/ICAAC1.gif)
![ICAAC2.gif](../images/092515/092515-6/ICAAC2.gif)
![ICAAC3.gif](../images/092515/092515-6/ICAAC3.gif)
![ICAAC4.gif](../images/092515/092515-6/ICAAC4.gif)
![ICAAC5.gif](../images/092515/092515-6/ICAAC5.gif)
![ICAAC6.gif](../images/092515/092515-6/ICAAC6.gif)
![ICAAC7.gif](../images/092515/092515-6/ICAAC7.gif)
![ICAAC8.gif](../images/092515/092515-6/ICAAC8.gif)
![ICAAC9.gif](../images/092515/092515-6/ICAAC9.gif)
![ICAAC10.gif](../images/092515/092515-6/ICAAC10.gif)
![ICAAC11.gif](../images/092515/092515-6/ICAAC11.gif)
|
|
|
![](images/null.gif) |
![](images/null.gif) |
|
|